PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

GLP-1 Receptor Agonists Show No Excess Bowel Obstruction Risk

GLP-1 receptor agonistssemaglutidedulaglutideliraglutideSGLT2 inhibitorsDPP-4 inhibitorstype 2 diabetesbowel obstructionileuspharmacoepidemiologycohort studydrug safety Endocrinology / Diabetes / Obesity

Background Information

GLP-1 receptor agonists show no increased bowel obstruction risk compared to SGLT2 inhibitors.

Patients and clinicians have raised concerns about the risk of bowel obstruction with glucagon-like peptide-1 receptor agonists (GLP-1RAs), impacting treatment choices for type 2 diabetes. In this large database study, GLP-1RA use was not linked to a higher risk of bowel obstruction or ileus compared to sodium-glucose cotransporter 2 inhibitors (SGLT2is), with a hazard ratio of 0.80. The findings reassure clinicians about the gastrointestinal safety of GLP-1RAs compared to SGLT2is for type 2 diabetes, supporting their use without increased concern for bowel obstruction. GLP-1 receptor agonists do not increase bowel obstruction risk versus SGLT2 inhibitors.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Matsuo Y, Okada A, Sakamoto T, Yasunaga H

Citation: Matsuo Y, Okada A, Sakamoto T, et al. Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study. Diabetes, obesity & metabolism. 2026;28(11):9941-9954. doi:10.1111/dom.71189

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.